Resvita Bio, Inc.
Publicly observedBerkeley, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Berkeley | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Resvita Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | LE1LFZE6EMK5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2023Publicly observed
NIH SBIR/STTR award: Skin probiotics to treat atopic dermatitis
USD 999,988.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2022Publicly observed
NIH SBIR/STTR award: Skin probiotics to treat Netherton Syndrome
USD 703,229.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.